Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Wolfe Research

Wolfe Research initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $20.00 price objective on the stock.

ORKA has been the subject of several other reports. Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, December 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics has an average rating of “Buy” and a consensus target price of $39.86.

Oruka Therapeutics Stock Down 8.5 %

NASDAQ ORKA opened at $13.08 on Tuesday. The business’s fifty day simple moving average is $17.88. The company has a market capitalization of $457.80 million, a PE ratio of -2.09 and a beta of 0.77. Oruka Therapeutics has a fifty-two week low of $10.95 and a fifty-two week high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of ORKA. FMR LLC acquired a new stake in Oruka Therapeutics in the third quarter valued at $114,763,000. RTW Investments LP bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $45,359,000. Franklin Resources Inc. acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $17,661,000. Braidwell LP bought a new position in shares of Oruka Therapeutics during the third quarter worth about $12,640,000. Finally, Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics in the third quarter worth approximately $12,614,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.